Pomerantz Law Firm Launches Investigation into ADMA Biologics Investors' Claims Amidst Controversial Reports

Investor Alert: Pomerantz Law Firm Investigates ADMA Biologics

In recent developments that have raised red flags among investors, Pomerantz LLP has initiated an inquiry into potential misconduct by ADMA Biologics, Inc. (NASDAQ: ADMA). This investigation follows serious allegations of securities fraud and deceptive business practices targeting the company and its top officials.

On March 24, 2026, a report from Culper Research accused ADMA of artificially inflating its growth figures, suggesting that the company manipulated its revenue through a scheme known as channel stuffing. According to the report, ADMA’s purported growth was significantly exaggerated, with claims that without these misleading practices, revenue for 2025 actually fell by 3% instead of reflecting the reported growth of 20%. Following the release of these findings, ADMA's stocks plummeted by $2.26, translating to a 16.63% drop, closing at $11.33.

Two days later, March 26, 2026, Cantor Fitzgerald downgraded ADMA's stock, expressing dissatisfaction with the company's vague response to the serious allegations highlighted by Culper Research. This decision further compounded the stock's decline, resulting in a $1.34 drop, marking a decrease of 13.91%, bringing the closing price down to $8.29.

On May 6, 2026, ADMA announced it would withdraw its long-term financial guidance, citing ongoing challenges posed by competitive dynamics in the U.S. plasma products and immunoglobulin markets. This revelation contributed to another significant reduction in stock value, with shares plummeting by $1.61, or nearly 16%, closing at $8.47 on May 7.

Pomerantz LLP, established over 85 years ago by pioneer Abraham L. Pomerantz, is recognized in the legal field for its dedication to representing victims of corporate fraud, including securities violations and breaches of fiduciary duty. With offices in major cities like New York, Los Angeles, and London, the firm continues its mission to ensure justice for investors through class actions against corporate misconduct.

Danielle Peyton of Pomerantz LLP encourages any investors affected by ADMA's actions to come forward and seek assistance. They can reach her directly at [email protected] or through the firm's contact number 646-581-9980, ext. 7980. The firm is currently gathering more information to determine the full scope of the alleged securities fraud and its implications for ADMA’s investors.

As this investigation unfolds, it serves as a stark reminder to investors about the importance of due diligence and vigilance when it comes to the companies they support. As Pomerantz continues its efforts, those involved with ADMA Biologics will likely keep a close watch on the developments from both the legal front and the market.